ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
A veteran in cell therapy and oncology commercialisation
All India Institute of Ayurveda hosts ministers and showcase their achievements
Subscribe To Our Newsletter & Stay Updated
